Home › Funds › Samsara BioCapital, LLC › NGNE

Samsara BioCapital, LLC position in NGNE

NEUROGENE INC · Health Care

Samsara BioCapital, LLC reported holding 1,867,127 shares of NGNE (NEUROGENE INC) in its Q3 2026 13F filing — a position valued at US$51.9M, representing 4.94% of its reported portfolio and ranking #7 among its reported holdings. Samsara BioCapital, LLC has disclosed NGNE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)1.87M sh
Reported value held$51.94M
Portfolio Weight4.94%
First reportedQ4 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Samsara BioCapital, LLC's NGNE position evolved

Samsara BioCapital, LLC first disclosed a stake in NGNE in Q4 2023 at 1,267,790 shares (US$24.6M). The position peaked in Q1 2024 at 1,267,790 shares, worth US$64.5M. Across 12 filings, Samsara BioCapital, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 1,867,127 shares valued at US$51.9M — an increase of 150,000 shares quarter over quarter.. Notable position changes include a 35% increase in Q4 2024 (shares fell 49% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 1.27M $24.57M New
Q1 2024 1.27M $64.53M Hold
Q2 2024 1.27M $46.13M Hold
Q3 2024 1.27M $53.20M Hold
Q4 2024 1.72M $39.25M Add
Q1 2025 1.72M $20.11M Hold
Q2 2025 1.72M $25.67M Hold
Q3 2025 1.72M $29.76M Hold
Q4 2025 1.72M $35.37M Hold
Q1 2026 1.72M $34.62M Hold
Q2 2026 1.72M $54.00M Hold
Q3 2026 1.87M $51.94M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NGNE and 13F data

NGNE (NEUROGENE INC) is a Health Care company. 41 other funds we track also report a position in NGNE — the largest reported positions include Casdin Capital (US$44.1M), Redmile Group, LLC (US$43.5M), RTW INVESTMENTS, LP (US$42.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NGNE

All NGNE fund holders →

FAQ

How long has Samsara BioCapital, LLC held NGNE?

Samsara BioCapital, LLC has disclosed NGNE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Samsara BioCapital, LLC's current position in NGNE?

As of Q3 2026, Samsara BioCapital, LLC holds 1.87M shares of NGNE (NEUROGENE INC), valued at $51.94M, representing 4.94% of its reported portfolio and ranking #7.

Has Samsara BioCapital, LLC been buying or selling NGNE?

In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC increased its position in NGNE. The position peaked in Q1 2024 at 1.27M shares.

Which other funds hold NGNE?

Other major institutional holders of NGNE include Casdin Capital, Redmile Group, LLC, RTW INVESTMENTS, LP, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.